Oncolytics Biotech Inc's Comment on Sales, Marketing and Customers
The company focuses on the oncology market, targeting cancers with significant unmet medical needs and large addressable markets. Its specific areas of focus include gastrointestinal cancers, particularly colorectal cancer (CRC) and KRAS-mutant MSS metastatic colorectal cancer (mCRC), as well as anal cancer and pancreatic cancer. The company highlights the high incidence and mortality rates of these cancers globally and in the United States, with market sizes projected to grow substantially by 2033-2035. It aims to develop treatments for patient populations with limited existing options, such as unresectable squamous cell anal carcinoma (SCAC) in second-line and later settings. The company operates in a highly competitive oncology market alongside pharmaceutical, biopharmaceutical, and biotechnology firms.
The global anal cancer treatment market is expected to see significant growth in the coming years, with projections indicating it will reach USD 1.63 billion by 2030. A recent article featured on the MD Anderson website highlights the rising prevalence of anal cancer, particularly among women, and the importance of early detection for successful treatment. The report also outlines the various types of anal cancer, including squamous cell cancer, adenocarcinomas, and skin cancers.According to Market Research Future, the anal cancer market is estimated to grow at a compound annual growth rate (CAGR) of 8.6% through 2030. This rare form of cancer originates in the anus, which is the opening at the end of the re...
Oncolytics Biotech Inc’s Comment on Sales, Marketing and Customers
The company focuses on the oncology market, targeting cancers with significant unmet medical needs and large addressable markets. Its specific areas of focus include gastrointestinal cancers, particularly colorectal cancer (CRC) and KRAS-mutant MSS metastatic colorectal cancer (mCRC), as well as anal cancer and pancreatic cancer. The company highlights the high incidence and mortality rates of these cancers globally and in the United States, with market sizes projected to grow substantially by 2033-2035. It aims to develop treatments for patient populations with limited existing options, such as unresectable squamous cell anal carcinoma (SCAC) in second-line and later settings. The company operates in a highly competitive oncology market alongside pharmaceutical, biopharmaceutical, and biotechnology firms.
Sources:
Oncolytics Biotech Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Oncolytics Biotech Inc’s corporate clients.
For your research, we’ve provided 9 tables on Oncolytics Biotech Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
